May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Ocular Hypotensive Efficacy of Brimonidine 0.15% as Adjunctive Therapy With Latanoprost 0.005% in Patients With Open–Angle Glaucoma or Ocular Hypertension
Author Affiliations & Notes
  • R.J. Noecker
    Ophthalmology, Univ, Pittsburgh, PA
  • M. Earl
    IMEDS, Riverside, CA
  • Footnotes
    Commercial Relationships  R.J. Noecker, Allergan, C; M. Earl, None.
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 445. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      R.J. Noecker, M. Earl; Ocular Hypotensive Efficacy of Brimonidine 0.15% as Adjunctive Therapy With Latanoprost 0.005% in Patients With Open–Angle Glaucoma or Ocular Hypertension . Invest. Ophthalmol. Vis. Sci. 2006;47(13):445.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the ocular hypotensive efficacy of brimonidine 0.15% (Alphagan P, Allergan) as adjunctive therapy with latanoprost 0.005% (Xalatan, Pfizer) in patients with open–angle glaucoma or ocular hypertension.

Methods: : Multicenter, open–label, prospective evaluation of 43 patients. Enrolled patients had an IOP > 18 mm Hg after at least 6 weeks of latanoprost monotherapy. The primary outcome measure was IOP at peak drug effect (10 AM, or approximately 2 hours after the morning dose of brimonidine 0.15%). IOP at trough drug effect (8 AM, or approximately 12 hours after the evening dose of brimonidine) was also measured.

Results: : Baseline IOP was 21.9 (± 2.3) mm Hg. After 1 month, the additional mean IOP reductions from a latanoprost–treated baseline were 5.8 mm Hg (26%) at peak drug effect (P<.001) and 3.3 mm Hg (15%) at trough (P<.001). At the month 2 visit, the additional mean IOP reductions from a latanoprost–treated baseline were 5.1 mm Hg (23%) at peak drug effect (P<.001) and 2.0 mm Hg (9%) at trough (P<.001).

Conclusions: : Brimonidine Purite 0.15% provided statistically significant additional reductions in IOP from a latanoprost–treated baseline. These findings suggest that brimonidine Purite 0.15% is an efficacious adjunctive therapy in patients using latanoprost who require additional IOP lowering.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×